

Editorial

New Synthetic Methodology for Drug-like Molecules

Graeme Barker ^{1,*}  and Simona Rapposelli ^{2,*} ¹ Institute of Chemical Sciences, Heriot-Watt University, Riccarton, Edinburgh EH14 4AS, UK² Department of Pharmacy, University of Pisa, 56126 Pisa, Italy

* Correspondence: graeme.barker@hw.ac.uk (G.B.); simona.rapposelli@unipi.it (S.R.)

The field of synthetic methodology plays a pivotal role in the quest for safe and effective drugs. It provides chemists with the tools and techniques necessary to create complex molecular architectures, enabling the discovery and production of innovative drug-like molecules. Since 2000, seven Nobel prizes in chemistry have been awarded for advances in fields that are directly relevant to modern pharmaceutical synthesis—in 2001, 2005, 2010, 2016, 2018, 2021 and 2022. This Special Issue of *Molecules* is dedicated to highlighting the latest advancements in synthetic methodology, which are propelling medicinal chemistry to new heights.

In this Special Issue, a diverse array of new methodologies for the synthesis of drug-like molecules is reported, highlighting the breadth of modern synthesis. Xu reviewed synthetic methods of preparing phosphonopeptides [1], phosphoramidite analogues of peptides that are widely applied in a range of therapeutic roles. Transition metal catalysis remains a cornerstone of synthesis, and herein, building on previous work in this field [2–4], Kharitonov and Shults report a Pd-catalysed route to isospongian diterpenoids that bear a marginatafuran skeleton reminiscent of furanyl analogues of steroids *via* a Heck–Suzuki cascade using readily available bromolabertianic acid [5]. Previous syntheses of these unusual structures relied on toxic Hg- or Sn-chemistry or expensive Indium reagents [6–8], and this convenient new route will facilitate the investigation of their biological activities. The importance of synthesis for investigating biological activity is further highlighted by France and co-workers [9], who studied the synthesis and enantiomeric resolution of both enantiomers and the racemate of PF74, a capsid-targeting inhibitor of HIV replication [10]. In so doing, they have addressed key questions regarding the importance of the PF74 stereogenic centre, and the (*S*)-enantiomer was revealed to be over an order of magnitude more active than the (*R*)-enantiomer.

Environmental concerns and the high cost of reagents have led to increased interest in transition metal-free synthetic methodologies in recent years, and several manuscripts in this Special Issue report developments in the utilization of this strategy. Zhao, Horsfall and Hulme report on the synthesis of spirocyclic analogues of cephalosporin antibiotics using an S_N2 /conjugate addition sequence to induce the reaction of catechols with a 3-chloromethylcephalosporin substrate [11]. The importance of cephalosporins in modern medicine is widely understood, while the advantages of the inherently 3-dimensional structure of spirocyclic compounds vs. flat amido- and heteroaromatics has recently been highlighted in terms of their increased facility towards protein–ligand interactions [12]. Bukhari et al. report on a convenient modified Biginelli protocol for the synthesis of dihydrouracil analogues [13], a crucial intermediate in the metabolic breakdown of uracils [14]. This simplified procedure offers considerable advantages over previously reported multi-step syntheses [15,16]. 2-Aminothiophenes are common drug moieties, with many extant bioactive examples additionally bearing 3-substituents [17–19]. Benfodda and co-workers report on the catalyst-free hydroxyalkylation of a 2-aminothiophene *via* a reaction with trifluoromethyl ketones [20], a remarkable achievement given the propensity of unprotected amines to form imines with carbonyl reagents. Weng et al. developed hypervalent



Citation: Barker, G.; Rapposelli, S. New Synthetic Methodology for Drug-like Molecules. *Molecules* **2023**, *28*, 5632. <https://doi.org/10.3390/molecules28155632>

Received: 13 July 2023

Accepted: 20 July 2023

Published: 26 July 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

iodine chemistry for the C2-arylacetylation of benzothiazoles via an unusual demethylative reaction of methylaryl ketones [21]. Benzothiazoles are well established as one of the most common ring systems in FDA-approved drugs [22], and 2-arylacyl examples encompass a broad range of bioactivities [23–28]. The implementation of enabling technologies, including continuous flow chemistry and electrosynthesis, remains a key area of interest, and Machado and co-workers report on the use of ultrasound-assisted synthesis to facilitate C-O bond forming reactions in the preparation of antitubercular drug candidates [29].

To conclude, synthetic methodology research remains in rude health, with several research groups having contributed a diverse array of novel approaches to synthesising prominent bioactive compounds and key structural moieties.

Acknowledgments: We thank all of the authors for their valuable contributions to this Special Issue; all the peer reviewers for their suggestions, criticism and comments to ensure that the work presented is of high quality; and the *Molecules* staff members for their support in preparing this issue.

Conflicts of Interest: The author declares no conflict of interest.

References

1. Xu, J. Synthetic methods of phosphonopeptides. *Molecules* **2020**, *25*, 5894. [[CrossRef](#)] [[PubMed](#)]
2. Chernov, S.V.; Shul'ts, E.E.; Shakirov, M.M.; Tolstikov, G.A. Synthetic transformations of higher terpenoids: XII. Transformation of lambertianic acid into 14, 16-epoxyabietane diterpenoids. *Russ. J. Org. Chem.* **2006**, *42*, 36–41. [[CrossRef](#)]
3. Shults, E.E.; Velder, J.; Schmalz, H.G.; Chernov, S.V.; Rubalova, T.V.; Gatilov, Y.V.; Henze, G.; Tolstikov, G.A.; Prokop, A. Gram-scale synthesis of pinusolide and evaluation of its antileukemic potential. *Bioorganic Med. Chem. Lett.* **2006**, *16*, 4228–4232. [[CrossRef](#)]
4. Kharitonov, Y.V.; Shul'ts, E.E.; Rybalova, T.V.; Pavlova, A.V.; Tolstikova, T.G. Synthetic Transformations of Higher Terpenoids. 40. Synthesis and Assessment of Analgesic Activity of N-Containing Derivatives of Lambertianic Acid. *Chem. Nat. Compd.* **2021**, *57*, 879–886. [[CrossRef](#)]
5. Kharitonov, Y.V.; Shults, E.E. An Approach toward 17-Arylsubstituted Marginatafuran-Type Isospongian Diterpenoids via a Palladium-Catalyzed Heck–Suzuki Cascade Reaction of 16-Bromolambertianic Acid. *Molecules* **2022**, *27*, 2643. [[CrossRef](#)] [[PubMed](#)]
6. Nishizawa, M.; Yamada, H.; Hayashi, Y. Cyclization control of ambliofuran analog: Effective total synthesis of (+)-baiyunol. *J. Org. Chem.* **1987**, *52*, 4878–4884. [[CrossRef](#)]
7. Pandey, U.C.; Sarmah, P.; Sharma, R.P. Polyene cyclization: Cyclization studies on an acyclic furanoditerpene and its epoxide. *Tetrahedron* **1984**, *40*, 3739–3748. [[CrossRef](#)]
8. Zhao, J.F.; Zhao, Y.J.; Loh, T.P. Indium tribromide-promoted arene-terminated epoxy olefin cyclization. *Chem. Commun.* **2008**, *11*, 1353–1355. [[CrossRef](#)]
9. Ruddell, S.; Sugrue, E.; Memarzadeh, S.; Hellam, L.M.; Wilson, S.J.; France, D.J. Synthesis, Enantiomeric Resolution and Biological Evaluation of HIV Capsid Inhibition Activity for Racemic,(S)- and (R)-PF74. *Molecules* **2021**, *26*, 3919. [[CrossRef](#)]
10. Blair, W.S.; Pickford, C.; Irving, S.L.; Brown, D.G.; Anderson, M.; Bazin, R.; Cao, J.; Ciaramella, G.; Isaacson, J.; Jackson, L.; et al. HIV capsid is a tractable target for small molecule therapeutic intervention. *PLoS Pathog.* **2010**, *6*, e1001220. [[CrossRef](#)]
11. Zhao, A.X.; Horsfall, L.E.; Hulme, A.N. New methods for the synthesis of spirocyclic cephalosporin analogues. *Molecules* **2021**, *26*, 6035. [[CrossRef](#)]
12. Zheng, Y.J.; Tice, C.M. The utilization of spirocyclic scaffolds in novel drug discovery. *Expert Opin. Drug Discov.* **2016**, *11*, 831–834. [[CrossRef](#)]
13. SBukhari, S.N.A.; Ejaz, H.; Elsherif, M.A.; Janković, N. Synthesis and Characterization of Dihydrouracil Analogs Utilizing Biginelli Hybrids. *Molecules* **2022**, *27*, 2939. [[CrossRef](#)] [[PubMed](#)]
14. Inada, M.; Hirao, Y.; Koga, T.; Itose, M.; Kunizaki, J.I.; Shimizu, T.; Sato, H. Relationships among plasma [2-¹³C] uracil concentrations, breath ¹³CO₂ expiration, and dihydropyrimidine dehydrogenase (DPD) activity in the liver in normal and DPD-deficient dogs. *Drug Metab. Dispos.* **2005**, *33*, 381–387. [[CrossRef](#)]
15. Wu, S.; Janusz, J.M. Solid-phase synthesis of 3-aminohydantoin, dihydrouracil, thiohydantoin and dihydrothiouracil derivatives. *Tetrahedron Lett.* **2000**, *41*, 1165–1169. [[CrossRef](#)]
16. Blanco-Ania, D.; Valderas-Cortina, C.; Hermkens, P.H.; Sliedregt, L.A.; Scheeren, H.W.; Rutjes, F.P. Synthesis of dihydrouracils spiro-fused to pyrrolidines: Druglike molecules based on the 2-arylethyl amine scaffold. *Molecules* **2010**, *15*, 2269–2301. [[CrossRef](#)] [[PubMed](#)]
17. Scheich, C.; Puetter, V.; Schade, M. Novel small molecule inhibitors of MDR Mycobacterium tuberculosis by NMR fragment screening of antigen 85C. *J. Med. Chem.* **2010**, *53*, 8362–8367. [[CrossRef](#)]
18. Narlawar, R.; Lane, J.R.; Doddareddy, M.; Lin, J.; Brussee, J.; IJerman, A.P. Hybrid ortho/allosteric ligands for the adenosine A1 receptor. *J. Med. Chem.* **2010**, *53*, 3028–3037. [[CrossRef](#)]
19. Tang, J.; Huber, A.D.; Pineda, D.L.; Boschert, K.N.; Wolf, J.J.; Kankanala, J.; Xie, J.; Sarafianos, S.G.; Wang, Z. 5-Aminothiophene-2, 4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors. *Eur. J. Med. Chem.* **2019**, *164*, 179–192. [[CrossRef](#)]

20. Duvauchelle, V.; Béniméris, D.; Meffre, P.; Benfodda, Z. Catalyst-free site selective hydroxyalkylation of 5-phenylthiophen-2-amine with α -trifluoromethyl ketones through electrophilic aromatic substitution. *Molecules* **2022**, *27*, 925. [[CrossRef](#)]
21. Sun, X.T.; Hu, Z.G.; Huang, Z.; Zhou, L.L.; Weng, J.Q. A Novel PIFA/KOH Promoted Approach to Synthesize C2-arylacetylated Benzothiazoles as Potential Drug Scaffolds. *Molecules* **2022**, *27*, 726. [[CrossRef](#)] [[PubMed](#)]
22. Taylor, R.D.; MacCoss, M.; Lawson, A.D. Rings in drugs: Miniperspective. *J. Med. Chem.* **2014**, *57*, 5845–5859. [[CrossRef](#)] [[PubMed](#)]
23. Miralinaghi, P.; Schmitt, C.; Hartmann, R.W.; Frotscher, M.; Engel, M. 6-Hydroxybenzothiophene Ketones: Potent Inhibitors of 17β -Hydroxysteroid Dehydrogenase Type 1 (17β -HSD1) Owing to Favorable Molecule Geometry and Conformational Preorganization. *ChemMedChem* **2014**, *9*, 2294–2308. [[CrossRef](#)]
24. Komiya, M.; Asano, S.; Koike, N.; Koga, E.; Igarashi, J.; Nakatani, S.; Isobe, Y. Synthesis of novel benzo-fused heteroaryl derivatives as Ca^{2+} /Calmodulin-dependent protein kinase II inhibitors. *Chem. Pharm. Bull.* **2013**, *61*, 1094–1097. [[CrossRef](#)]
25. Myllymäki, M.J.; Saario, S.M.; Kataja, A.O.; Castillo-Melendez, J.A.; Nevalainen, T.; Juvonen, R.O.; Järvinen, T.; Koskinen, A.M. Design, synthesis, and in vitro evaluation of carbamate derivatives of 2-benzoxazolyl- and 2-benzothiazolyl-(3-hydroxyphenyl)-methanones as novel fatty acid amide hydrolase inhibitors. *J. Med. Chem.* **2007**, *50*, 4236–4242. [[CrossRef](#)]
26. Tang, G.; Nikolovska-Coleska, Z.; Qiu, S.; Yang, C.Y.; Guo, J.; Wang, S. Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins. *J. Med. Chem.* **2008**, *51*, 717–720. [[CrossRef](#)] [[PubMed](#)]
27. Chen, J.; Li, C.M.; Wang, J.; Ahn, S.; Wang, Z.; Lu, Y.; Dalton, J.T.; Miller, D.D.; Li, W. Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization. *Bioorg. Med. Chem.* **2011**, *19*, 4782–4795. [[CrossRef](#)]
28. Hu, E.; Kunz, R.K.; Chen, N.; Rumpf, S.; Siegmund, A.; Andrews, K.; Chmait, S.; Zhao, S.; Davis, C.; Chen, H.; et al. Design, optimization, and biological evaluation of novel keto-benzimidazoles as potent and selective inhibitors of phosphodiesterase 10A (PDE10A). *J. Med. Chem.* **2013**, *56*, 8781–8792. [[CrossRef](#)]
29. Borsoi, A.F.; Paz, J.D.; Pissinate, K.; Rambo, R.S.; Pestana, V.Z.; Bizarro, C.V.; Basso, L.A.; Machado, P. Ultrasound-Assisted synthesis of 4-alkoxy-2-methylquinolines: An efficient method toward antitubercular drug candidates. *Molecules* **2021**, *26*, 1215. [[CrossRef](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.